This site is intended for healthcare professionals
News

Merck Inc., and Ridgeback announce submission of Emergency Use Authorization application to the FDA for molnupiravir, an oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults.

Read time: 1 mins
Last updated:12th Oct 2021
Published:12th Oct 2021
Merck Inc.,and Ridgeback Biotherapeutics announced that Merck has submitted an Emergency Use Authorization (EUA) application to the FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights